Berberine vs Semaglutide: Which Is Better for Weight Loss?
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
- Berberine
- Semaglutide
Every intervention Outliyr has scored for female fertility, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for female fertility; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
20 of 72 evaluated interventions score 3.0+ out of 10 for female fertility · 4 comparisons
The evidence supports a use-case score of 6.8/10 for Metformin in female fertility, based on the meta-analysis of 13 randomized trials that reported higher ovulation odds (Lord 2003). Metformin targets insulin resistance,…
Read the Metformin report →Female fertility receives a 6.8/10 Tirzepatide score because weight loss and insulin improvement can indirectly help ovulatory function, especially in obesity-linked PCOS patterns Franco 2025. The limitation is direct evidence: fertility endpoints…
Read the Tirzepatide report →Female fertility scores 6.0/10 on PCOS ovulation-induction data. A meta-analysis of eight RCTs (n=910) by Thakker 2015 found NAC improved ovulation (pooled OR 3.13), pregnancy (OR 3.58), and live birth (OR 3.00)…
Read the NAC (N-Acetylcysteine) report →Fertility Female is a 6.0/10 use case for Berberine, not a blanket claim. Female fertility relevance is mainly PCOS ovulation restoration through insulin sensitization. This score is capped by pregnancy avoidance requirements…
Read the Berberine report →Fertility-female scores 5.5/10 because weight loss and insulin improvement can support ovulation in PCOS or obesity-linked infertility, but Semaglutide must be stopped before conception. Moiz 2024 supports meaningful weight loss, which is…
Read the Semaglutide report →High-Dose Melatonin has female-fertility relevance, though much of the direct IVF evidence uses lower doses. The assisted-reproduction meta-analysis reported improved clinical pregnancy odds with melatonin among randomized trials (Hu et al. 2020).…
Read the High-Dose Melatonin report →Female fertility is the best-validated use, again driven by kisspeptin-54 rather than kisspeptin-10. A single subcutaneous dose triggered egg maturation at every dose tested across 53 women in IVF, with embryo transfer…
Read the Kisspeptin-10 report →The practical fertility-female read on Zone 2 Cardio is 5.0/10 because Vabishchevich 2026 anchors the strongest signal. The existing rationale points to this narrower claim: Moderate aerobic training supports insulin sensitivity, body…
Read the Zone 2 Cardio report →No direct female-fertility evidence was verified. Pregnancy and fertility claims should defer to standard prenatal nutrition guidance.
Read the Essential Amino Acids report →No direct female-fertility RCT evidence for glycine supplementation.
Read the Glycine report →No direct female fertility evidence. Pregnancy is a contraindication, so fertility-adjacent claims need caution.
Read the Whole-Body Vibration report →Female fertility scores 4.5/10. CoQ10 is widely used in assisted reproduction for older women on the theory of supporting oocyte mitochondrial function, and small trials show improved ovarian response markers. But clean…
Read the Coenzyme Q10 (CoQ10 / Ubiquinol) report →No direct female-fertility evidence. Avoid in pregnancy and lactation because safety data are insufficient.
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Female sexual-function data is not the same as fertility evidence. V0 preserved a modest score because direct female fertility RCT evidence is thin, and pregnancy remains an avoidance context. Ashwagandha should not…
Read the Ashwagandha report →Female fertility response is bimodal. Mavropoulos 2005 supports pilot-level PCOS benefit through lower insulin and androgen markers. In lean eugonadal women, lower free sex hormones, T3 shifts, and amenorrhea risk can move…
Read the Ketogenic Diet report →Female-fertility use is not clinically established. Resveratrol's phytoestrogen activity creates both theoretical upside and theoretical downside depending on tissue context, ovarian status, endometrial biology, and cancer risk. No robust human fertility RCT…
Read the Resveratrol report →One small RCT in pregnant women; HPA modulation plausible. Pregnancy is documented safe context.
Read the HRV Biofeedback report →Maleki-Hajiagha 2024 and Rodrigues 2025 support selected ART lab endpoints, but not broad pregnancy-outcome certainty.
Read the Astaxanthin report →Muniandy 2025 adds the first larger Physta menopause RCT signal for quality of life and sexual-domain improvement, but pregnancy and lactation remain excluded by EFSA 2021 and female fertility itself has not…
Read the Tongkat Ali report →Female fertility evidence is limited. Pregnancy outcome evidence is stronger than pre-conception fertility evidence.
Read the Omega-3 report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
Kisspeptin-10 scores 6.4 and TRT 5.7, and TRT still wins 13 of the 15 use cases both reports score. The higher number reflects dependency and reversibility, not effect.…
Metformin scores 6.9 and berberine 6.8, so the gap is meaningless. Metformin owns blood sugar with decades of outcome trials behind it. Berberine owns fatty liver, needs no…
CoQ10 scores 7.1 and urolithin A scores 6.5, so CoQ10 wins on the numbers and costs two to six times less. It takes cardiovascular, energy, antioxidant and both…
Metformin, at 6.8 out of 10 for female fertility. The evidence supports a use-case score of 6.8/10 for Metformin in female fertility, based on the meta-analysis of 13 randomized trials that reported higher ovulation odds (Lord 2003).
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 4.5 out of 10 for female fertility.
20 of the 72 interventions evaluated for female fertility score 3.0 out of 10 or better, which is the cut-off for appearing on this page.